Please check your internet connection and try again.
# Lucast Plus
## Overview
**Lucast Plus** is a combination product typically containing **Montelukast** (a leukotriene receptor antagonist) and **Levocetirizine** (a second-generation H1-receptor antagonist) or sometimes **Montelukast** and **Fexofenadine**. *Note: Formulation composition can vary by manufacturer and region; always verify the specific active ingredients on the product label.*
## Primary Indications
* Allergic rhinitis (seasonal and perennial).
* Adjunctive management of asthma associated with allergic rhinitis.
## Adult Dosing
* **Standard Dose:** 1 tablet (containing Montelukast 10 mg and Levocetirizine 5 mg) administered orally once daily, typically in the evening.
## Pediatric Dosing
* **Safety Warning:** Fixed-dose combinations are generally not recommended for children < 6 years or those weighing < 20 kg due to lack of dosage flexibility.
* **Children 6 to 12 years:** Consult specific product labeling. Often 1/2 of an adult tablet or a pediatric-specific formulation (if available). Do not prescribe unless the product is specifically FDA/EMA-approved for the pediatric age group.
## Dose Adjustments
* **Renal Impairment:** Dose reduction or increased dosing intervals are required if the component is Levocetirizine (CrCl < 50 mL/min).
* **Hepatic Impairment:** Monitor patients with hepatic insufficiency; no specific guidelines exist for the combination, but Montelukast should be used with caution in severe impairment.
## Contraindications
* Hypersensitivity to montelukast, levocetirizine (or cetirizine), or any component.
* Severe renal impairment (end-stage renal disease, hemodialysis) if containing levocetirizine.
* History of neuropsychiatric events associated with montelukast (use caution).
## Adverse Effects
* **Common:** Somnolence, fatigue, dry mouth, headache, nasopharyngitis.
* **Serious:** Neuropsychiatric events (agitation, aggression, depression, sleep disturbances, suicidal ideation) associated with montelukast.
## Key Drug Interactions
* **CNS Depressants:** May potentiate the sedative effects of levocetirizine (alcohol, benzodiazepines, opioids).
* **CYP450 Inducers:** Phenobarbital, phenytoin, or rifampin may decrease montelukast plasma concentrations.
* **Ritonavir:** May increase plasma levels of levocetirizine.
## Monitoring
* **Neuropsychiatric:** Monitor for mood shifts, behavioral changes, or signs of depression during montelukast therapy.
* **Renal Function:** Assess baseline CrCl if levocetirizine is present.
## Clinical Pearls
* **Timing:** Administer in the evening to optimize control of allergic symptoms and minimize the impact of slight sedation from the antihistamine component.
* **Behavioral Safety:** The FDA issued a boxed warning for montelukast regarding serious neuropsychiatric events; use only when benefit outweighs risk.
* **Local Protocols:** Because this is a combination product, always prioritize individual monotherapy components unless the fixed-dose combination provides a demonstrated clinical advantage for patient compliance.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Verify all dosages, contraindications, and drug-drug interactions against current institutional protocols, local prescribing information (e.g., package insert), and up-to-date clinical databases (e.g., Lexicomp, Micromedex) before prescribing or administering medication.
